HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E4616 Buloxibutid Buloxibutid (AT2 Agonist C21) is a selective agonist of angiotensin II type 2 receptor (AT2R) with a Ki value of 0.4 nM for the AT2 receptor and a Ki >10 µM for the AT1 receptor. Its treatment significantly reduces vascular remodelling, improves hemodynamics, and decreases pulmonary collagen deposition in the Sugen-Hypoxia model of pulmonary hypertension. Aug 07 2024
S8625 GNE-049 GNE-049 is a highly potent and selective inhibitor of CBP. It exhibits an IC50 of 1.1 nM in TR-FRET assay. GNE-049 also effectively inhibits BRET and BRD4 with IC50 values of 12 nM and 4200 nM, respectively. Aug 06 2024
E4856 Rotigotine Hydrochloride Rotigotine Hydrochloride (N-0923 Hydrochloride) is a potent Agonist of dopamine receptor, with Ki values of 0.71 nM for dopamine D3 receptor, 4-15 nM for D2, D5, D4 receptors, and 83 nM for dopamine D1 receptor. It also acts as a partial agonist of the 5-HT1A receptor, and as an antagonist of the α2B-adrenergic receptor. Aug 06 2024
E1041 SY-5609 SY-5609 (CDK7-IN-3) is an orally active and highly selective inhibitor of CDK7 with a KD value of 0.065 nM. SY-5609 exhibits poor inhibition on CDK2, CDK9, CDK12. SY-5609 displays antitumor activity and can induce apoptosis in tumor cells. Aug 06 2024
E1823 Ninerafaxstat trihydrochloride Ninerafaxstat trihydrochloride (MB-1018972 trihydrochloride, IMB-101 trihydrochloride) acts as a competitive inhibitor of 3-ketoacyl-CoA thiolase (3-KAT) to partially suppress fatty acid oxidation. It is an orally active cardiac mitochondrial drug that restores myocardial energy homeostasis. Ninerafaxstat trihydrochloride regulates myocardial substrate utilization and improves cardiac efficiency. Ninerafaxstat trihydrochloride is also used in research of cardiovascular diseases. Aug 06 2024
E4850 Tazemetostat hydrobromide Tazemetostat hydrobromide (EPZ-6438 hydrobromide) is a potent, selective, and orally available inhibitor of EZH2. It inhibits EZH2 with IC50 values of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat hydrobromide also inhibits EZH1 with an IC50 of 392 nM. Aug 06 2024
E1565 Iruplinalkib Iruplinalkib (WX-0593) is a highly selective oral inhibitor of ALK and ROS1 tyrosine kinase. It exhibits potent and promising antitumor activity in advanced non-small cell lung cancer (NSCLC) with ALK or ROS1 rearrangement. Aug 01 2024
E4632 Taminadenant Taminadenant (NIR178, PBF509) is a non-xanthine and non-furan antagonist of adenosine A2A receptor (A2AR). It can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with Kb values of 72.8 nM and 8.2 nM, respectively. It exhibits potential utility for Parkinson’s disease (PD) treatment. Aug 01 2024
E4636 W-7 hydrochloride W-7 hydrochloride is a potent antagonist of calmodulin (CaM) that inhibits Dengue virus (DENV) translation and replication. It also competitively inhibits Trypsin-treated Ca2+/calmodulin-dependent phosphodiesterase (Ca2+-PDE). It exhibits anti-proliferative and anti-tumor effect. Aug 01 2024
E1426 EAPB02303 EAPB02303 is a second-generation imiqualine that acts as a microtubule -disruptingagent and demonstrates anti-tumor effects and reduces tumor size in human melanoma xenografts. Aug 01 2024
E4841 Vorapaxar sulfate Vorapaxar sulfate (SCH 530348 sulfate) is a selective and orally active antagonist of protease-activated receptor (PAR-1), with a Ki value of 8.1 nM. Vorapaxar sulfate reduces thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner. Aug 01 2024
E4838 Cefuroxime Cefuroxime (Kefurox) is an orally active, second-generation, broad-spectrum cephalosporin antibiotic with increased stability to β-lactamase. Cefuroxime exhibits broad-spectrum activity against Gram-positive bacteria including penicillinase-producing staphylococci and non-β-lactamase-producing gram-negative bacteria. Aug 01 2024
E1403 Fumarate hydratase-IN-1 Fumarate hydratase-IN-1 is a small molecule cell-permeable inhibitor of fumarate hydratase. It induce alteration of TCA cycle metabolites, modulation of cytosolic processes, and substantial redox stress responses. Jul 29 2024
P1242 Proteinase K Proteinase K is a serine endoprotease, is used for isolating amyloid cores and is effective over a wide pH range (4–12), including in the presence of SDS or urea. It is commonly used as a preparative reagent for destruction of proteins, including DNAses and RNAses, in DNA and RNA preparations. Jul 29 2024
E1611 Atuzabrutinib Atuzabrutinib (SAR 444727, PRN473) is a reversible, selective inhibitor of Bruton's tyrosine kinase (Btk). It can effectively prevent neutrophil recruitment via inhibition of macrophage antigen‐1 signalling. Jul 25 2024
E1791 Zongertinib Zongertinib (BI 1810631, BI 764532) is a selective and potent inhibitor of human HER2 and EGFR tyrosine kinase that covalently binds to both wild-type and mutated HER2 receptors, including exon 20 insertion mutations, while sparing EGFR signaling. It exhibits effective and tolerable oral treatment for patients with HER2 aberration-positive solid tumors. Jul 25 2024
E1931 AD-5584 AD-5584 is a specific inhibitor of human acyl-CoA synthetase short chain family member 2 (ACSS2). It significantly reduces lipid storage, decreases colony formation, and increases cell death in vitro, while also confirming blood-brain barrier (BBB) permeability. Jul 25 2024
E1533 Lipofermata Lipofermata is an inhibitor of fatty acid transport protein 2 (FATP2) that demonstrates fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. It may offer therapeutic potential for diseases where lipotoxicity is a key factor. Jul 25 2024
E1877 BLU 451(LNG-451) BLU 451 (LNG-451) is a central nervous system (CNS)-penetrant, wild-type EGFR-sparing, covalent inhibitor of epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) with an IC50 of 7-78 nM. It also exhibits a potent anti-tumor efficacy. Jul 24 2024
E4827 Diphenhydramine Diphenhydramine is a first-generation antihistamine and sedative that acts as an antagonist of the H1 receptor and is used for treating acute allergic reactions. It is FDA-approved as an adjunct to epinephrine and corticosteroids and exhibits anticholinergic and antiemetic effects. Jul 23 2024